Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 billion between 2019 and 2023, a U.S. government watchdog's report showed this ...

Diabetes mortality declined in the U.S. by 32.1% from 2000 to 2019, with decreases in mortality observed among all racial and ...

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed ... leader in the class with sales of $4.12 billion in 2019. Lilly said last week that there was no sign yet that the ...